Literature DB >> 9436874

Treatment of Acanthamoeba keratitis.

T D Lindquist1.   

Abstract

PURPOSE: To review the available treatment modalities for Acanthamoeba keratitis and to assess the most effective regimens.
METHODS: The efficacy of therapeutic modalities and chemotherapeutic agents used in the treatment of Acanthamoeba keratitis was reviewed. Potential synergistic or additive drug interactions were documented both in vitro and in vivo.
RESULTS: Early diagnosis of Acanthamoeba keratitis plays a crucial role in successful medical treatment. The cationic antiseptic agents, chlorhexidine and polyhexamethylene biguanide (PHMB) have the lowest minimal amoebicidal concentrations. Synergistic effects are seen when used with pentamidine, and additive effects are seen with propamidine or neomycin. Penetrating keratoplasty should be deferred if at all possible until a medical cure has been achieved.
CONCLUSION: Early diagnosis and wide epithelial debridement are important elements in the successful treatment of Acanthamoeba keratitis. Recommended therapy would include the cationic antiseptic agents, chlorhexidine or PHMB in combination with propamidine isethionate and neomycin as part of triple therapy. Surgical intervention should be avoided until a medical cure has been achieved.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9436874     DOI: 10.1097/00003226-199801000-00002

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  10 in total

1.  Viability of Acanthamoeba after exposure to a multipurpose disinfecting contact lens solution and two hydrogen peroxide systems.

Authors:  K Hiti; J Walochnik; E M Haller-Schober; C Faschinger; H Aspöck
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

2.  Acanthamoeba species Keratitis in a Soft Contact Lens Wearer Molecularly Linked to Well Water.

Authors:  Samira Mubareka; Michelle Alfa; Godfrey K Harding; Gregory Booton; Marilyn Ekins; Paul Vancaeseele
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-03       Impact factor: 2.471

3.  Patient characteristics, diagnosis, and treatment of non-contact lens related Acanthamoeba keratitis.

Authors:  S Sharma; P Garg; G N Rao
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

4.  Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis.

Authors:  Rebecca A Kuennen; Reynell Harder Smith; Thomas F Mauger; Elson Craig
Journal:  Clin Ophthalmol       Date:  2010-10-05

5.  Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.

Authors:  Karim Makdoumi; Anders Bäckman; Jes Mortensen; Anders Magnuson; Sven Crafoord
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-19       Impact factor: 3.117

Review 6.  Acanthamoeba spp. as agents of disease in humans.

Authors:  Francine Marciano-Cabral; Guy Cabral
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

7.  Delay in diagnosis and outcome of Acanthamoeba keratitis.

Authors:  I Claerhout; A Goegebuer; C Van Den Broecke; Ph Kestelyn
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-08       Impact factor: 3.117

8.  Clinical and histologic evaluations of experimental Acanthamoeba keratitis.

Authors:  Zubeyde Akin Polat; Semra Ozcelik; Ayse Vural; Esin Yildiz; Ali Cetin
Journal:  Parasitol Res       Date:  2007-08-14       Impact factor: 2.289

9.  Histopathological examination of Acanthamoeba sclerokeratitis.

Authors:  Kumiko Kato; Koji Hirano; Tetsuro Nagasaka; Koichi Matsunaga; Yuko Takashima; Mineo Kondo
Journal:  Clin Ophthalmol       Date:  2014-01-16

Review 10.  Ocular Surface Infection Mediated Molecular Stress Responses: A Review.

Authors:  Samayitree Das; Sharon D'Souza; Bhavya Gorimanipalli; Rohit Shetty; Arkasubhra Ghosh; Vrushali Deshpande
Journal:  Int J Mol Sci       Date:  2022-03-14       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.